Similarly, although PD-L1 biomarker information was not available in our dataset, use of 1 L IO monotherapy in the United Kingdom during the study period was restricted to patients with a PD-L1 tumor proportion score of ≥50%; thus, it is likely that only patients with a PD-L1 tumor proportion score ≥ 50% received IO monotherapy in this population. Here, CD274 is linked to neoplasm.